Congress Asset Management Co. Buys 10,721 Shares of Insulet Corporation $PODD

Congress Asset Management Co. raised its stake in Insulet Corporation (NASDAQ:PODD) by 11.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,518 shares of the medical instruments supplier’s stock after purchasing an additional 10,721 shares during the quarter. Congress Asset Management Co. owned approximately 0.14% of Insulet worth $28,571,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. SG Americas Securities LLC raised its stake in shares of Insulet by 1,359.0% during the 4th quarter. SG Americas Securities LLC now owns 39,261 shares of the medical instruments supplier’s stock worth $11,160,000 after purchasing an additional 36,570 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Insulet by 18.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 156,979 shares of the medical instruments supplier’s stock valued at $44,620,000 after buying an additional 24,761 shares in the last quarter. Diversified Trust Co. grew its stake in shares of Insulet by 495.7% in the fourth quarter. Diversified Trust Co. now owns 8,102 shares of the medical instruments supplier’s stock valued at $2,303,000 after buying an additional 6,742 shares in the last quarter. Gradient Investments LLC increased its holdings in Insulet by 17.9% during the fourth quarter. Gradient Investments LLC now owns 69,161 shares of the medical instruments supplier’s stock worth $19,658,000 after buying an additional 10,497 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in Insulet by 22.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,819 shares of the medical instruments supplier’s stock worth $1,419,000 after acquiring an additional 888 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Stifel Nicolaus cut their price target on shares of Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research note on Wednesday, February 4th. Raymond James Financial lowered their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Leerink Partners dropped their target price on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Citigroup cut their target price on shares of Insulet from $345.00 to $338.00 and set a “buy” rating for the company in a research note on Wednesday, March 11th. Finally, Barclays reiterated an “underweight” rating and set a $286.00 price target on shares of Insulet in a report on Thursday, February 19th. Twenty research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $354.24.

Insulet Trading Down 0.7%

PODD stock opened at $225.50 on Wednesday. Insulet Corporation has a one year low of $216.49 and a one year high of $354.88. The stock has a market cap of $15.88 billion, a price-to-earnings ratio of 64.43, a price-to-earnings-growth ratio of 1.36 and a beta of 1.42. The company has a fifty day moving average price of $250.03 and a two-hundred day moving average price of $291.12. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The company had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company’s revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 earnings per share. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling

In related news, Director Michael R. Minogue purchased 2,030 shares of the stock in a transaction on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.